BioMarin Pharmaceutical | BMRN - Loan Capital


BioMarin Pharmaceutical reported $597.18M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Bayer EUR 31.83B 877M Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Incyte USD 30.2M 5.17M Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Ionis Pharmaceuticals USD 1.9B 1.87B Dec/2025
Moderna USD 610M 584M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 15.72B 150.06M Dec/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025